LDS/Medical Tests/Small Nuclear Ribonucleoprotein Polypeptide N and Ubiquitin Protein Ligase E3A (SNRPN/UBE3A) Methylation Analysis

Small Nuclear Ribonucleoprotein Polypeptide N and Ubiquitin Protein Ligase E3A (SNRPN/UBE3A) Methylation Analysis

SNRPN and UBE3A genes are located in the same region, chromosome 15 at position 11.2 and encode small nuclear ribonucleoprotein-associated protein N protein and ubiquitin-protein ligase E3A (UBE3A), respectively. SNRPN protein plays a role in pre-mRNA processing, and possibly tissue-specific alternative splicing events. The protein arises from a bicistronic transcript that also encodes a protein identified as the SNRPN upstream reading frame (SNURF).

UBE3A encodes for E3-ubiquitin-protein ligase and functions in the ubiquitin protein degradation system. Deletions in the maternal allele of UBE3A gene in the 15q11.2-q13 regions is responsible for Angelman syndrome (AS). Approximately 65-75% of AS patients have a maternally derived deletion with another 3% to 10% of AS cases resulting from paternal uniparental disomy (UPD) or imprinting defects. Approximately 11% of AS cases result from mutations in the maternal copy of the UBE3A gene that also maps to 15q11.2-q13.

Clinically, AS is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and a unique behavior with an inappropriate happy demeanor that includes frequent laughing, smiling, and excitability (‘happy puppet’). Microcephaly and seizures are also common. Developmental delays are first noted at around age six months; however, the unique clinical features of AS do not become manifest until after 12 months. Prevalence of AS is estimated to be one in 12,000-24,000 individuals.

The loss of the paternally contributed 15q11.2-q13 region is associated with Prader-Willi syndrome (PWS). PWS is a multisystem disorder characterized by severe hypotonia, global developmental delay, feeding difficulties and failure to thrive in the newborn period, followed by hyperphagia (excessive eating) and development of morbid obesity in late infancy and early childhood. Characteristic physical features include short stature, strabismus, almond-shaped palpebral fissures, narrow nasal bridge, thin upper lip with down-turned mouth, and scoliosis. Hypopigmentation of hair, eyes, and skin are seen in a third of the affected individuals. PWS has an estimated incidence of 1 in 15,000-25,000 live births. PWS may be caused by large deletions in paternal 15q11-q13 (75-80%), maternal uniparental disomy (matUPD) (20-25%), imprinting defects (~1%), and imprinting center deletions (10-15% of those with an imprinting defect).

DNA methylation testing is done to detect abnormal parent specific imprinting within 15q11.2-q13 regions. This testing confirms the clinical diagnosis of Prader-Willi syndrome and Angelman syndrome. However, to help determine whether there are risks of Prader-Willi syndrome in other family members it may be necessary to perform FISH, UPD and/or imprinting center testing to determine the exact cause of the abnormal methylation.

  • Diagnostic confirmation of Prader-Willi syndrome and Angelman syndrome (AS)
  • To differentiate between Prader-Willi syndrome and Angelman syndrome for patients with 15q11.2-q13 deletion without the need for the analysis of parental samples
  • To differentiate between Prader-Willi syndrome caused by paternal deletion or UPD/Imprinting defect
  • For prenatal testing and family planning

Positive

  • Prader-Willi Syndrome positive: Absence of paternal methylation patterns.
  • Angelman Syndrome positive: Absence of maternal methylation patterns.
  • Methylation testing can detect approximately 99% of the Prader-Willi syndrome cases and 80% of Angelman syndrome cases and it is considered as confirmatory testing for diagnosis.
  • Will also distinguish deletion from disomy (UPD and ID); but will not distinguish UPD from ID
  • Can give approximate size of deletion and identify type 1 and 2 deletions
  • Can also detect most IC and SNORD116 microdeletions

Negative: Detection of maternal and paternal methylation patterns

Methylation Specific PCR; Differential methylation at the CpG island of the SNRPN/ UBE3A gene is detected using a bisulfite conversion of methylated DNA, followed by PCR amplification with allele specific primers and detection by agarose gel electrophoresis. This distinguishes the methylated (maternal) and unmethylated (paternal) copies of the gene. Methylation-specific multiplex ligation-dependent probe amplification (MLPA) can detect the deletion along with the methylation assay amplification.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Chromosomal microarray analysis (CMA), FISH (fluorescence in situ hybridization) analysis, deletion/duplication analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Front Endocrinol (Lausanne). 2019;10: 864. [PMID: 31920975]
  • Cell. 2015;162: 795-807. [PMID: 26255772]
  • Am J Med Genet A. 2011;155A: 81-90. [PMID: 21204213]
  • GeneReviews® [Internet]. J Mol Diagn. 2011; 13: 108-112. [PMID: 21227401]
  • BMC Med Genet. 2010;11: 70. [PMID: 20459762]
  • GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1330/
  • GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1144/
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/UBE3A#
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/SNRPN#